Newbridge Bancorp (NBBC) 10.93 $NBBC BUYINS.NET: SPA,

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Newbridge Bancorp (NBBC) 10.93 $NBBC

BUYINS.NET: SPA, BZH, CVGI, GCBC, NBBC, PRSS, Expected to Trade Higher After Bullish Insider Trading
M2 - Wed Feb 10, 12:25PM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. Sparton Corp (NYSE:SPA), Beazer Homes USA Inc (NYSE:BZH), Commercial Vehicle Group Inc (NASDAQ:CVGI), Greene County Bancorp Inc (NASDAQ:GCBC), NewBridge Bancorp (NASDAQ:NBBC), CafePress Inc (NASDAQ RSS) are all expected to go Higher as Buy signals have been generated by top insider trading patterns.
PRSS: 3.09 (+0.05), NBBC: 10.93 (-0.42), SPA: 22.99 (+0.86), GCBC: 16.77 (+0.05), BZH: 8.36 (+0.38), CVGI: 4.52 (-0.01)

NewBridge Bancorp reports Q4 2015 net income of USD3.4m
M2 - Fri Feb 05, 6:45AM CST
NewBridge Bancorp (NASDAQ: NBBC) has reported net income available to common shareholders totaled USD3.4 million, or USD0.09 per share, compared to USD4.3 million, or USD0.11 per diluted share, for the quarter ended December 31, 2014, the company said. For the 12 months ended December 31, 2015, net income available to common shareholders totaled USD18.8 million, or USD0.48 per diluted share. Net interest income was USD22.8 million for the fourth quarter of 2015, compared with USD21.3 million for the quarter ended December 31, 2014 and USD22.9 million for the quarter ended September 30, 2015. The increase year over year was primarily due to loan growth and also reflected the effect of the Premier acquisition in the first quarter of 2015. Total average interest-earning assets increased to USD2.58 billion at December 31, 2015 from USD2.30 billion at December 31, 2014. Total noninterest income for the fourth quarter of 2015 was USD4.1 million, stable from the fourth quarter of 2014. Mortgage banking revenue increased substantially to USD422,000, up 94.5 percent from USD217,000 a year earlier, and reflected strong growth in mortgage loan production. Total noninterest expense increased 13.1 percent to USD21.0 million. In the fourth quarter of 2015, noninterest expense included USD2.1 million in acquisition related expenses primarily for the Yadkin merger; whereas in the fourth quarter of 2014 acquisition related expenses primarily for Premier were only USD171,000. Total assets grew to USD2.81 billion at December 31, 2015, up 1.3 percent from USD2.77 billion at September 30, 2015, and up 11.5 percent from USD2.52 billion at December 31, 2014. NewBridge Bancorp is the holding company for NewBridge Bank, a USD2.8 billion community focused bank headquartered in Greensboro, North Carolina. Through 42 branches, NewBridge Bank provides personal financial solutions including banking, lending, and wealth management services.
NBBC: 10.93 (-0.42)

BUYINS.NET: NBBC, CPRX, MPB, LTXB, Expected to Trade Higher After Bullish Insider Trading
M2 - Tue Feb 02, 9:03AM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. NewBridge Bancorp (NASDAQ:NBBC), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), Mid Penn Bancorp Inc (NASDAQ:MPB), (NASDAQ:LTXB) are all expected to go Higher as Buy signals have been generated by top insider trading patterns.
CPRX: 0.80 (+0.03), MPB: 15.85 (+0.13), NBBC: 10.93 (-0.42), LTXB: 26.56 (+0.50)

NewBridge posts 4Q profit
Automated Insights - Thu Jan 28, 4:59PM CST
GREENSBORO, N.C. (AP) _ NewBridge Bancorp (NBBC) on Thursday reported fourth-quarter net income of $3.4 million.
NBBC: 10.93 (-0.42)

NewBridge Bancorp (Nasdaq: NBBC) Announces Fourth Quarter 2015 Results
PR Newswire - Thu Jan 28, 3:15PM CST
Fourth Quarter and Year-to-Date 2015 Highlights
NBBC: 10.93 (-0.42)

BUYINS.NET: IMH, GABC, CNBKA, AUBN, TUES, NBBC, Expected to Trade Higher After Bullish Insider Trading
M2 - Mon Jan 25, 8:49AM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. Impac Mortgage Holdings Inc (NYSE:IMH), German American Bancorp Inc (NASDAQ:GABC), CENTURY BANCORP, INC. (NASDAQ:CNBKA), Auburn National Bancorporation Inc (NASDAQ:AUBN), Tuesday Morning Corp (NASDAQ:TUES), NewBridge Bancorp (NASDAQ:NBBC) are all expected to go Higher as Buy signals have been generated by top insider trading patterns.
CNBKA: 42.36 (+0.82), GABC: 32.64 (+0.91), NBBC: 10.93 (-0.42), IMH: 17.67 (+0.49), TUES: 7.48 (+0.56), AUBN: 28.00 (-0.64)

NewBridge Bancorp Announces Fourth Quarter Cash Dividend
PR Newswire - Wed Nov 18, 3:15PM CST
NewBridge Bancorp (NASDAQ: NBBC) announced today the fourth quarter cash dividend payable to its common shareholders. On November 18, 2015, the Board of Directors of NewBridge Bancorp declared a $0.015 per share quarterly cash dividend on its common stock, payable January 15, 2016 to shareholders of record as of the close of business on December 16, 2015.
NBBC: 10.93 (-0.42)

NewBridge Bancorp (NASDAQ: NBBC) Reports Solid Third Quarter 2015 Results
PR Newswire - Thu Oct 22, 3:15PM CDT
Shareholder Value
NBBC: 10.93 (-0.42), YDKN: 25.58 (+0.36)

NEWBRIDGE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of NewBridge Bancorp (NBBC) Over the Proposed Sale of the Company to Yadkin Financial Corporation
PR Newswire - Tue Oct 20, 9:33AM CDT
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NewBridge Bancorp ("NewBridge" or the "Company" (NasdaqGS:NBBC) for potential breaches of fiduciary duties in connection with the sale of the Company to Yadkin Financial Corporation for approximately $456 million.
NBBC: 10.93 (-0.42), YDKN: 25.58 (+0.36)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of NewBridge Bancorp of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Yadkin Financial Corporation
BusinessWire - Mon Oct 19, 1:48PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
NBBC: 10.93 (-0.42), YDKN: 25.58 (+0.36)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of NewBridge Bancorp of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Yadkin Financial Corporation -- NBBC
PR Newswire - Fri Oct 16, 9:23AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
NBBC: 10.93 (-0.42), YDKN: 25.58 (+0.36)

NEWBRIDGE BANCORP INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NewBridge Bancorp
PR Newswire - Tue Oct 13, 6:31PM CDT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF" are investigating the proposed sale of NewBridge Bancorp ("NewBridge" or the "Company" (NASDAQ: NBBC) to Yadkin Financial Corporation (NYSE: YDKN). Under the terms of the proposed transaction, shareholders of NewBridge will receive only 0.50 shares of Yadkin for each share of NewBridge that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
YDKN: 25.58 (+0.36), NBBC: 10.93 (-0.42)

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of NewBridge Bancorp And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Tue Oct 13, 5:15PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of NewBridge Bancorp (NasdaqGS: NBBC) ("NewBridge" or the "Company" relating to the proposed buyout of the Company by Yadkin Financial Corporation, in a transaction valued at approximately $456 million.
NBBC: 10.93 (-0.42)

EQUITY ALERT: Rosen Law Firm Announces Investigation of NewBridge Bancorp Concerning its Proposed Sale to Yadkin Financial Corporation
BusinessWire - Tue Oct 13, 2:49PM CDT
Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of NewBridge Bancorp (NASDAQ:NBBC) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop NewBridge to maximize shareholder value before agreeing to be acquired by Yadkin Financial Corporation (NYSE:YDKN).
YDKN: 25.58 (+0.36), NBBC: 10.93 (-0.42)

Yadkin Financial Corporation and NewBridge Bancorp Announce Signing of Definitive Merger Agreement
GlobeNewswire - Tue Oct 13, 6:18AM CDT
Yadkin Financial Corporation (NYSE:YDKN) (or "Yadkin" and NewBridge Bancorp (NASDAQ:NBBC) (or "NewBridge" jointly announced today that they have entered into a definitive merger agreement, pursuant to which Yadkin will acquire NewBridge. The combination will strengthen Yadkin as the largest community bank headquartered in North Carolina.
NBBC: 10.93 (-0.42), YDKN: 25.58 (+0.36)

NewBridge Bancorp declares dividend of USD0.015 per share for Q3 2015
M2 - Fri Aug 21, 4:06AM CDT
NewBridge Bancorp (NASDAQ:NBBC) declared on Thursday that it will pay a third quarter cash dividend of USD0.015 per share on its common stock, as approved by its board of directors.
NBBC: 10.93 (-0.42)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 143

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 352

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 134

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 0

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 37

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 163

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

BerGenBio Welcomes First Patient in Lung Cancer Study

Updated Category News Views 202

BerGenBio Embarks on Promising Lung Cancer Trial BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as...

Continue Reading
CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform

Updated Category News Views 247

CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform CIMG Inc. (NASDAQ: IMG), a dynamic group in the digital health and sales development sector, has officially launched its tokenized stock on the FlowStocks platform. This exciting development follows successful testing and represents a significant shift in how the company interacts with its investors. The new...

Continue Reading
Exploring the Impact of New SEC Leadership on Cryptocurrency

Updated Category News Views 179

New Era for Cryptocurrency Under SEC Leadership The recent changes at the Securities and Exchange Commission (SEC) under new leadership signal a transformative period for the cryptocurrency market. These developments could reshape the regulatory landscape, offering clarity and direction for investors and companies involved in the digital asset space. Understanding the...

Continue Reading
Shytoshi Kusama Transitions Roles: Shiba Inu's New Direction

Updated Category News Views 190

Shytoshi Kusama Transitions to New Leadership Role Shytoshi Kusama, the driving force behind the Shiba Inu ecosystem, has made a significant change by stepping down from his role as the lead visionary. This pivotal shift marks a transition to the position of lead ambassador, as he aims to spearhead global adoption more effectively. The Shift in Leadership Announcing his...

Continue Reading
BASF Shares Fall Following Proposed Dividend Cuts to Shareholders

Updated Category News Views 281

BASF (ETR:BASFN) just took a hit on its stock price after announcing some major shifts in its dividend policy. Shares plummeted by 2.9% to €44.035, all thanks to the company's new proposed minimum annual dividend of €2.25 per share for the upcoming 2024 business year. That’s a stark drop from the previous €3.40 per share they dished out in 2023—talk about making...

Continue Reading